bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: J J M A M F J
2018: D N O S A J

  Broad-Range Ebola Drug Shows Promise in Animal Tests

By Robert Preidt

FRIDAY, Jan. 11, 2019 (HealthDay News) -- An experimental Ebola drug was effective against all strains of the deadly virus in laboratory animals, scientists say.

Previous research typically took the "one bug, one drug" approach, said researcher Thomas Geisbert, a professor at the University of Texas Medical Branch at Galveston. But due to the unpredictable nature of Ebola, scientists have been trying to develop protection against multiple strains of the virus, he added.

A single dose of a two-antibody drug fully protected monkeys and ferrets against the Bundibugyo and Sudan strains, as well as the deadliest Zaire strain responsible for the 2013-2016 epidemic in West Africa and the current outbreak in the Democratic Republic of Congo, the researchers said. The drug is called MBP134.

"Our experimental drug can protect against all forms of Ebola known to harm people, suggesting that it will continue to protect people if the Ebola viruses evolve over time," Geisbert said in a school news release.

"We were able to protect the nonhuman primates against all the Ebola species plaguing people at a single low dose," said Larry Zeitlin, president of drug maker Mapp Biopharmaceutical Inc. of San Diego.

Further studies using even lower doses could open the door to auto-injector treatment like the kind used for allergic reactions, Zeitlin said.

However, it's important to note that results of animal experiments aren't necessarily applicable to humans.

Still, "the ability to quickly and efficiently provide protection against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure," Zeitlin added.

The research was published Jan. 9 in the journal Cell Host & Microbe.

More information

The U.S. Centers for Disease Control and Prevention has more on Ebola.

SOURCE: University of Texas Medical Branch at Galveston, news release, Jan. 9, 2019

Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=741404

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Sprains and Strains
Research Personnel
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact